When endothelium does not function, it leads to corneal homeostasis loss, leading to severe vision loss. Credit: Che / Petr Novák, Wikipedia

The US Food and Drug Administration (FDA) has granted Breakthrough Status designation to EyeYon Medical’s artificial endothelial layer implant EndoArt.

EndoArt, made of polymer film, attaches to the posterior corneal surface to treat chronic corneal oedema secondary to endothelial dysfunction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

When endothelium does not function, it leads to corneal homeostasis loss due to excess fluid flowing into the cornea, leading to severe vision loss.

EyeYon Medical CEO and co-founder Nahum Ferera said: “Receiving Breakthrough Device Designation for our revolutionary EndoArt implant is an important milestone in accelerating the path to the market, affecting the quality of life of millions of patients.

“We look forward to collaborating with the FDA to speed the clinical development of EndoArt so that it can be used to treat a condition that impacts the lives of so many.”

EndoArt is minimally invasive and suture-free, designed to replace dysfunctional endothelium in patients where human donor tissue has failed to cure oedema.

According to the company, both preclinical and early human clinical studies indicated a significant reduction in oedema in affected eyes.

Currently, there is no adequate solution for patients with corneal oedema other than undergoing corneal transplant surgery.

Globally, 13 million affected patients are waiting for corneal tissue. The company claims a significant number of patients would benefit if approved from EndoArt development.

EyeYon Medical develops medical ophthalmic devices. Its first product was Hyper-CL therapeutic contact lens to treat various corneal pathologies, such as corneal oedema and erosions. Hyper-CL lens received the CE Mark and FDA clearance for marketing in Europe and the USA.